CORDIS
EU research results

CORDIS

English EN

Cost-effective microfluidic electronic devices for optimal drug administration based on fractional pharmacokinetics for leukemia treatments

Project information

Grant agreement ID: 690876

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.1.3.3.

  • Overall budget:

    € 333 000

  • EU contribution

    € 283 500

Coordinated by:

UNIVERZITET U NOVOM SADU

Serbia

Objective

The project entitled: “Cost-effective microfluidic electronic devices for optimal drug administration based on fractional pharmacokinetics for leukemia treatments”, with acronym MEDLEM, has a general objective to foster exchanging knowledge and sharing different culture and approaches in reaching high level of excellence, in research and innovation, in the framework of this field.

The project is aimed at strengthening research collaboration through active networking, staff exchange and dissemination activities between 4 European organizations from Serbia, Germany and France as well as 2 non-European institutions from Thailand and Australia, in linking the fields of microfluidic electronic devices, optimal drug administration, fractional pharmacokinetics, and leukemia treatments. The project will exploit complementary competencies and synergies of the participants, and enable knowledge sharing via international/inter-sectoral mobility, based on secondments of research staff. The consortium offers a unique opportunity that creativity and entrepreneurship will flourish and will help exchanged personnel to turn creative ideas into innovative electronics products, reaching breakthroughs in modelling, drug administration and improvements in therapy protocols.

The main technical goals of the joint research programme are:
- Development of fractional pharmacokinetic models and procedures for parameter identification within these models;
- Design and fabrication of microfluidic device with in-built electronics for optimal drug delivery protocol;
- Pharmacokinetics determination of the pharmaceuticals for leukemia treatments and its testing in vitro and in vivo systems;
- Optimal control problem, its numerical solution and implementation.

The proposal will develop new research links and strengthen the current research links among the partners and will help build up long-term, world-class research in more successful leukemia treatments.

Coordinator

UNIVERZITET U NOVOM SADU

Address

Dr Zorana Dindica 1
21000 Novi Sad

Serbia

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 166 500

Participants (3)

ELVESYS

France

EU Contribution

€ 45 000

MARCOTECH OHG MARKETING, CONTROLLING AND TECHNOLOGY MANAGEMENT

Germany

EU Contribution

€ 40 500

GENOCHEM

France

EU Contribution

€ 31 500

Partners (2)

PRINCE OF SONGKLA UNIVERSITY

Thailand

CURTIN UNIVERSITY OF TECHNOLOGY

Australia

Project information

Grant agreement ID: 690876

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.1.3.3.

  • Overall budget:

    € 333 000

  • EU contribution

    € 283 500

Coordinated by:

UNIVERZITET U NOVOM SADU

Serbia